Cellular Intelligence Acquires Novo Parkinson's Therapy
Cellular Intelligence acquired Novo Nordisk's Parkinson's cell therapy. The firm will use its AI platform to accelerate development and reduce production costs.
Xurve View
Insights:
Xurve View
Cellular Intelligence acquired a Parkinson's disease cell therapy candidate from Novo Nordisk for an undisclosed sum and equity stake. The deal follows the October closure of the cell therapy unit by the drugmaker based in Denmark. Investors gain exposure to an AI-driven biotech leveraging META PLATFORMS INC-CLASS A CEO Mark Zuckerberg's philanthropic backing.
